In a Senate hearing, Robert F. Kennedy, Jr. said that efforts to address the high rates of chronic disease need to start with ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Robert F. Kennedy Jr.’s anti-vaccine advocacy is outside the mainstream. His previous statements on abortion could alienate ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...

The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...

Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...

A front-of-package food label would be a great educational tool. The Trump administration should keep it.

After 20 years of hemming, hawing, and “evaluating the science,” the FDA is finally muscling its way onto the most coveted ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...